Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.58 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.52 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.52 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.52 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.51 |
| ▸ | AMY2A | P04746 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 6/20 | 0.48 |
| ▸ | FGF1 | P05230 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215700 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL7743926 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL13125623 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL7146285 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL20658640 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL23475838 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL7871307 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL18821917 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL12070983 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL14421628 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023814-B2 | Glycomimetic compounds as anti-infectious against pathogens lectins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-05-05 | — | — | US | disclosed |
| US-20130252910-A1 | GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-26 | — | — | US | disclosed |
| US-20130224761-A1 | NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PORPHYRIN BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252910-A1 | GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS | SIGLEC7, SIGLEC9, LGALS1 | LGALS8 14/4885LGALS3 5/4885LGALS4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.